This model shows the Pharmaceutical New Drug Pipeline based on drug release, approval and patent expiry. This pipeline is then linked to patients switching from older drugs to newer drugs based on proven indications and marketing (indication creep). Based on work by Mark Heffernan on the Australian Pharmaceutical Benefits Scheme for drug subsidy.Conference paper and Larger ithink model